Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ARNT | P27540 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13897380 | 1.00 | CISD1 (0.41) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL3868501 | 1.00 | CISD1 (0.41) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL3865373 | 0.90 | ALOX5 (0.39) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL3865368 | 0.90 | ALOX5 (0.39) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL13897302 | 0.90 | ALOX5 (0.39) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL13897303 | 0.86 | CISD1 (0.38) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL3862679 | 0.86 | CISD1 (0.38) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL3862680 | 0.86 | CISD1 (0.38) | CISD1ALOX5MEN1KMT2AGAA | |
| SCHEMBL5512359 | 0.86 | CISD1 (0.37) | CISD1ALOX5MEN1KMT2ACTNNB1 | |
| SCHEMBL13897286 | 0.83 | CISD1 (0.36) | CISD1ALOX5MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | claimed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | claimed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084804-A1 | Quinazoline thiazolinones | CDK1, CDK14, CDK18 | CISD1 1093/4885ALOX5 4757/4885MEN1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.